CE for Pharmacists: CGRP Treatments: Their Role in Migraine Therapy
by Melissa Smith, 2023 PharmD Candidate, Alexandra Falk, 2021 PharmD Candidate, Ashley Alter, 2021 PharmD Candidate, Maddie Wiarek, 2022 PharmD Candidate, Kelsey Kapinus, 2023 PharmD Candidate, Beth Martin, RPh, MS, PhD
"Migraine headache is the third most common disease worldwide, in both males and females. Neurologists and primary care providers continue to encounter patients with migraines in their practice daily, with migraine accounting for the second leading cause of time spent living with disability worldwide. There are different types of migraine; however, the most prevalent is migraine without aura (see Table 1). According to the third edition of the International Classification of Headache Disorders (ICHD), migraine without aura is characterized by headache with a combination of recurring neurological symptoms and specific features. This can include recurrent headache attacks lasting 4-72 hours with moderate to severe pulsating or throbbing pain located on one side of the head (unilateral). Other disabling symptoms include nausea and/or vomiting, and sensitivity to light and sound. Patients with migraine headache usually need to stop all activities and rest. Some patients may describe an aura that precedes the migraine headache for 5-30 minutes, characterized by either visual or sensory changes, or speech or motor changes that are reversible. Aura is considered a prodrome, or warning sign, that signals migraine headache pain may follow. Migraine with aura is associated with increased cardiovascular and cerebrovascular risks and outcomes. Regardless of sex, patients who suffer from migraine with aura are at a greater risk for ischemic and hemorrhagic stroke as well as myocardial infarction.4 Due to this relationship, choosing medications with lower risks for cardiovascular and cerebrovascular events is essential for patients experiencing migraines with aura."
Keywords: Speech, Neurologists, Migraine without Aura, Headache, Nausea, Vomiting, Epilepsy, Primary Health Care, Serotonin, Analgesics, Opioid, Nasal Sprays, Tryptamines, Migraine with Aura, Calcitonin, Hemorrhagic Stroke, Migraine Disorders, Serotonin Receptor Agonists, Headache Disorders, Secondary
Download PDF
2021 September/October Table of Contents
"Migraine headache is the third most common disease worldwide, in both males and females. Neurologists and primary care providers continue to encounter patients with migraines in their practice daily, with migraine accounting for the second leading cause of time spent living with disability worldwide. There are different types of migraine; however, the most prevalent is migraine without aura (see Table 1). According to the third edition of the International Classification of Headache Disorders (ICHD), migraine without aura is characterized by headache with a combination of recurring neurological symptoms and specific features. This can include recurrent headache attacks lasting 4-72 hours with moderate to severe pulsating or throbbing pain located on one side of the head (unilateral). Other disabling symptoms include nausea and/or vomiting, and sensitivity to light and sound. Patients with migraine headache usually need to stop all activities and rest. Some patients may describe an aura that precedes the migraine headache for 5-30 minutes, characterized by either visual or sensory changes, or speech or motor changes that are reversible. Aura is considered a prodrome, or warning sign, that signals migraine headache pain may follow. Migraine with aura is associated with increased cardiovascular and cerebrovascular risks and outcomes. Regardless of sex, patients who suffer from migraine with aura are at a greater risk for ischemic and hemorrhagic stroke as well as myocardial infarction.4 Due to this relationship, choosing medications with lower risks for cardiovascular and cerebrovascular events is essential for patients experiencing migraines with aura."
Keywords: Speech, Neurologists, Migraine without Aura, Headache, Nausea, Vomiting, Epilepsy, Primary Health Care, Serotonin, Analgesics, Opioid, Nasal Sprays, Tryptamines, Migraine with Aura, Calcitonin, Hemorrhagic Stroke, Migraine Disorders, Serotonin Receptor Agonists, Headache Disorders, Secondary
Download PDF
2021 September/October Table of Contents